Latest Piperazines Stories

Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML. Blocking this growth factor increases the life expectancy of these mice, even in those resistant to imatinib.Chronic myeloid...

FRANKLIN LAKES, N.J. and PORTLAND, Ore., June 2, 2011 /PRNewswire/ -- Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. today announce the launch of a personalized medicine program for chronic myeloid leukemia (CML) patients. Through this program, Medco will offer patients diagnosed with CML a molecular test known as qRT-PCR (quantitative real-time polymerase chain reaction) BCR-ABL to monitor the disease. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO ) The...

The evidence base for the prescribing of aripiprazole in maintenance treatment of bipolar disorder is limited to a single trial, sponsored by the manufacturer of aripiprazole, according to a rigorous appraisal of the evidence for its use led jointly by Alexander Tsai of Harvard University, Boston USA, and Nicholas Rosenlicht of the University of California San Francisco, USA. In the paper, published in this week's PLoS Medicine, the authors describe key limitations of the trial, which were...

TITUSVILLE, N.J., April 11, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) on April 6 approved INVEGA® (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age. The efficacy of INVEGA® to treat schizophrenia in adolescents was established in one six-week clinical study. INVEGA® is an atypical antipsychotic medication and was first approved in the U.S. in December 2006 for the treatment of schizophrenia in...

While the median age at diagnosis for chronic myeloid leukemia (CML) is over 60 years old and incidence increases dramatically with age,limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML. Results from a study published today in Blood, the Journal of the American Society of Hematology, reveal that age does not affect response to imatinib and study investigators conclude that overall survival for CML...

Patients taking imatinib (Gleevec) for CML, or chronic myelogenous leukemia, and in remission after two years of treatment, have a mortality rate similar to that of the general population according to a study published online [date] in the Journal of the National Cancer Institute.The article offers the first evidence that a disseminated cancer, not amenable to surgery, can be controlled to the point of giving patients a normal life expectancy.Many patients in this study, known as the...

A warning issued by the Food and Drug Administration regarding the use of atypical antipsychotics for the treatment of dementia was associated with a significant decline in the use of these medications for treating dementia symptoms in elderly patients, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals."In 2001, more than 70 percent of U.S. atypical antipsychotic prescriptions were written for off-label indications such as...

Prescriptions of second-generation medications were already declining before FDA 'black box' warning, according to U-M analysisAs loved ones with dementia disappear into symptoms of aggression, agitation or delusions, families are left with few good medical solutions. A new generation of antipsychotic medications gained popularly in the 1990s because they avoided side effects such as Parkinson's syndrome associated with conventional antipsychotic medications used to treat dementia.But a new...

(Ivanhoe Newswire) -- Top-selling drugs, known as atypical antipsychotic medications, lack evidence that they'll actually be beneficial, according to a new study. Drugs in this class may cause serious effects such as weight gain, diabetes, and heart disease, along with costing Americans billions of dollars."Because these drugs have safety issues, physicians should prescribe them only when they are sure patients will get substantial benefits," Randall Stafford, M.D., Ph.D., associate...

Researchers from the Stanford University School of Medicine and the University of Chicago have found that many people currently using a specific type of antipsychotic medication are doing so for a condition that the drug has not yet been proven effective in treating.According to their findings, published online Friday in the journal Pharmacoepidemiology and Drug Safety, atypical antipsychotic medications were originally approved by the Food and Drug Administration (FDA) in 1989 for treating...